期刊
ALLERGY
卷 75, 期 7, 页码 1555-1563出版社
WILEY
DOI: 10.1111/all.14256
关键词
asthma; biologics; eosinophils; IgE; inflammation
资金
- Respiratory Effectiveness Group
New therapeutic options for severe asthma have recently emerged, mostly in the form of monoclonal antibodies (biologicals) targeting relevant inflammatory pathways. Currently available agents target different aspects of Type 2 immunity, and their indications often include overlapping patient groups. We present a round-table discussion that took place during the Annual Meeting of the Respiratory Effectiveness Group (REG), on the reasoning behind the use of different add-on medications for severe asthma, and crucially, on selection strategies. The proposed rational is based on current evidence, including real-life studies, as well as on the appreciation of the relevant complexities. Direct head-to-head comparisons of biologicals are lacking; therefore, algorithms for initial choice and potential switch between agents should be based on understanding the key characteristics of different options and the development of a clear plan with predefined targets and shared decision-making, in a structured way.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据